Date: 2015-11-16
Type of information: Nomination
Compound:
Company: Hybrigenics (France)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 16, 2015, Hybrigenics announced the first meeting of its newly assembled Clinical Advisory Board (CAB) which took place on November 10th, 2015 at its headquarters in Paris. The topics of this meeting were acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Hybrigenics’ CAB is composed of three American and two French clinical experts in hematologic oncology: - Prof. J. Cortes, Chair of the AML and CML sections, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, - Prof. O. Hermine, Chair of the Department of Hematology, Necker Hospital, Paris, - Prof. M. Mauro, Leader of the Myeloproliferative Diseases Program, Memorial SloanKettering Cancer Center, New York, - Prof. M. Tallman, Chief of the Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, - Prof. A. Thuran, Chair of the Department of Hematology, Kremlin-Bicetre Hospital, France. Hybrigenics is currently conducting a Phase II clinical study of oral inecalcitol in CML patients in France only. Hybrigenics is also preparing another Phase II clinical trial of oral inecalcitol in elderly or frail AML patients, an indication for which it has received Orphan Drug designation both in Europe and in the United States. This AML study aims at being performed both in France and in the United States. Prof. O. Hermine and Prof. J. Cortes will be the principal investigators in their respective country.
Financial terms:
Latest news:
